Market Research Logo

Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016

Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Review, H1 2016’, provides in depth analysis on Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted pipeline therapeutics.

The report provides comprehensive information on the Somatostatin Receptor Type 2 (SRIF-1 or SSTR2), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Somatostatin Receptor Type 2 (SRIF-1 or SSTR2)
  • The report reviews Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Somatostatin Receptor Type 2 (SRIF-1 or SSTR2)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) Overview
Therapeutics Development
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Stage of Development
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Therapy Area
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Indication
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Companies
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Products under Development by Universities/Institutes
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Companies Involved in Therapeutics Development
Boehringer Ingelheim GmbH
Crinetics Pharmaceuticals, Inc.
Ipsen S.A.
OctreoPharm Sciences GmbH
Progenics Pharmaceuticals, Inc.
Sompharmaceuticals S.A.
Strongbridge Biopharma plc
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Drug Profiles
BIM-23A758 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
COR-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Edotreotide Labeled Yttrium 90 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FX-125L - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-02113 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
lanreotide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OPS-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize SSTR4 and SSTR2 for Chronic Pain and Neuropathic Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Antagonize Somatostatin Receptor Type 2 for Neuroendocrine Tumors - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Dormant Projects
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Discontinued Products
Somatostatin Receptor Type 2 (SRIF-1 or SSTR2) - Featured News & Press Releases
Oct 15, 2015: Ipsen Announces Eight Studies of Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors Being Presented at the North American Neuroendocrine Tumor Society Symposium
Oct 06, 2015: Health Canada Approves Somatuline Autogel (lanreotide) Injection for the treatment of enteropancreatic neuroendocrine tumours
May 14, 2015: Ipsen Announces Data Presentations for Somatuline Depot (lanreotide) in Gastroenteropancreatic Neuroendocrine Tumors at American Society of Clinical Oncology Annual Meeting
Apr 27, 2015: Crinetics Pharmaceuticals Awarded NIH Fast-Track Grant to Develop Somatostatin Receptor Agonist Drugs for Chronic Pain
Apr 14, 2015: MHRA approves Ipsen’s Somatuline (lanreotide) Autogel 120mg as a new treatment for gastroenteropancreatic tumours
Jan 13, 2015: Ipsen Biopharmaceuticals to Present Further Data on Recently FDA-Approved Antitumor Therapy, Somatuline Depot (lanreotide), at Gastrointestinal Cancers Symposium
Dec 16, 2014: Ipsen’s Somatuline Depot is the first therapy approved by the FDA in the United States for the treatment of patients with locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors
Nov 06, 2014: Ipsen Announces FDA Approval of a New Delivery Device for Somatuline Depot (lanreotide) Injection
Sep 01, 2014: Ipsen Announces Acceptance of Filings for Somatuline in the Treatment of GEP-NET1s in the US with Priority Review and in Europe
Jul 16, 2014: New England Journal of Medicine Publishes Ipsen’s Somatuline CLARINET Phase III Results in Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumors
Jul 01, 2014: Ipsen submits marketing authorization applications in the US and Europe for Somatuline (lanreotide) in the treatment of gastroenteropancreatic neuroendocrine tumors
Apr 22, 2014: Aspireo Reports Data in Further Phase Ib Study
Jan 22, 2014: Ipsen Implements a New Governance in the United States to Prepare for the Launch of Somatuline in Oncology
Jan 17, 2014: Ipsen announces at ASCO GI that ELECT clinical trial of Somatuline in the control of symptoms in GEP-NET1 patients with carcinoid syndrome met its primary endpoint
Jan 14, 2014: Ipsen to set up its own US oncology team for Somatuline Depot Injection in neuroendocrine tumors
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by Boehringer Ingelheim GmbH, H1 2016
Pipeline by Crinetics Pharmaceuticals, Inc., H1 2016
Pipeline by Ipsen S.A., H1 2016
Pipeline by OctreoPharm Sciences GmbH, H1 2016
Pipeline by Progenics Pharmaceuticals, Inc., H1 2016
Pipeline by Sompharmaceuticals S.A., H1 2016
Pipeline by Strongbridge Biopharma plc, H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Discontinued Products, H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report